(Q36924418)

17 August 2017

Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer (English)

1 reference

17 August 2017

phase II clinical trial

0 references

1 reference

1 reference

1 reference

7

Cezary Cybulski

1 reference

17 August 2017

1

Tomasz Byrski

1 reference

17 August 2017

11

Jan Lubinski

1 reference

17 August 2017

12

Steven A Narod

1 reference

17 August 2017

6

Tomasz Huzarski

1 reference

17 August 2017

5

Jacek Gronwald

1 reference

17 August 2017

3

Pawel Blecharz

1 reference

17 August 2017

10

Andrea Eisen

1 reference

17 August 2017

8

Elzbieta Marczyk

1 reference

17 August 2017

9

Robert Chrzan

1 reference

Małgorzata Foszczyńska-Kłoda

17 August 2017

series ordinal

4

object named as

Malgorzata Foszczynska-Kloda

1 reference

17 August 2017

Rebecca Dent

2

1 reference

17 August 2017

20 July 2012

1 reference

17 August 2017

Breast Cancer Research

1 reference

17 August 2017

14

1 reference

17 August 2017

4

1 reference

17 August 2017

R110

1 reference

https://scigraph.springernature.com/pub.10.1186/bcr3231

17 August 2017

0 references

cites work

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3680929

Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3680929

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3680929

Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3680929

The resurgence of platinum-based cancer chemotherapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3680929

Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3680929

Targeting the DNA repair defect of BRCA tumours

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3680929

The role of BRCA1 in the cellular response to chemotherapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3680929

A high proportion of founder BRCA1 mutations in Polish breast cancer families

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3680929

Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3680929

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3680929

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3680929

Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3680929

Cisplatin as first-line therapy for metastatic breast cancer

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3680929

BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3680929

Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3680929

BRCA1-positive breast cancers in young women from Poland.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3680929

Improved survival in women with BRCA-associated ovarian carcinoma

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3680929

A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3680929

“BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated WithBRCA1andBRCA2Mutations

4 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2FBCR3231

The contribution of founder mutations to early-onset breast cancer in French-Canadian women

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2FBCR3231

Tumour biological features of BRCA1-induced breast and ovarian cancer

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22817698

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

BRCA2 hereditary breast cancer pathophenotype

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22817698

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22817698

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/BCR3231

1 reference

Dimensions Publication ID

17 August 2017

0 references

1 reference

17 August 2017

PubMed publication ID

22817698

1 reference